Last update 16 Apr 2025

RB-0004

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
RB 0004, RB-0004, RB0004
Target
PD-1
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication-
Inactive Indication
Cancer with a high tumour mutational burdenLymphomaMicrosatellite instability-high cancer
Originator Organization
Ruiyang Pharmaceutical Co., Ltd.Ruiyang Pharmaceutical Co., Ltd.
Active Organization-
Inactive Organization
Reyoung (suzhou) Biology Science & Technology Co LtdReyoung (suzhou) Biology Science & Technology Co Ltd
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with RB-0004
CTR20202500
/ CompletedPhase 1
RB0004 注射液用于标准治疗无效或无标准治疗的实体瘤的安全性、耐 受性和药代动力学特征的开放、单次/多次给药I 期临床试验
[Translation] An open, single/multiple-dose Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of RB0004 injection for solid tumors that are refractory to or without standard treatment
100 Clinical Results associated with RB-0004
Login to view more data
100 Translational Medicine associated with RB-0004
Login to view more data
100 Patents (Medical) associated with RB-0004
Login to view more data
100 Deals associated with RB-0004
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cancer with a high tumour mutational burdenPhase 1
China
Reyoung (suzhou) Biology Science & Technology Co LtdReyoung (suzhou) Biology Science & Technology Co Ltd
18 Mar 2021
LymphomaPhase 1
China
Reyoung (suzhou) Biology Science & Technology Co LtdReyoung (suzhou) Biology Science & Technology Co Ltd
18 Mar 2021
Microsatellite instability-high cancerPhase 1
China
Reyoung (suzhou) Biology Science & Technology Co LtdReyoung (suzhou) Biology Science & Technology Co Ltd
18 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free